PRES following administration of DHE in a patient with unsuspected pheochromocytoma.
We describe neurological complications which manifested after a patient with unsuspected pheochromocytoma was administered dihydroergotamine. Following administration of dihydroergotamine, the patient developed Balint syndrome, with the appearance of symmetric, bilateral occipital signal change on magnetic resonance imaging suggestive of posterior reversible encephalopathy syndrome.
Kelley
Brendan J
BJ
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Samples
Stephen
S
Kunkel
Robert
R
D000328:Adult; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects*; D004087:Dihydroergotamine / Q000009:adverse effects*; D006261:Headache / Q000139:chemically induced*; D006801:Humans; D020343:Hypertensive Encephalopathy / Q000139:chemically induced*; D008297:Male; D010673:Pheochromocytoma / Q000188:drug therapy; D012640:Seizures / Q000139:chemically induced*; D014786:Vision Disorders / Q000139:chemically induced*
D018712:Analgesics, Non-Narcotic; D004087:Dihydroergotamine